Pulse Biosciences CS (PLSE)

$17.50 -0.58 (-3.18%)
Market Cap 1.22B
Revenue (ttm) 0.00
Net Income (ttm) -53.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 223,800
Avg Vol 186,980
Day's Range N/A - N/A
Shares Out 67.30M
Stochastic %K 30%
Beta 1.79
Analysts Sell
Price Target $22.00

Company Profile

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cyc...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 510 906 4600
Address:
601 Brickell Key Drive, Suite 1080, Miami, United States
TruthBroker2
TruthBroker2 Oct. 27 at 12:18 PM
$SMMT $PLSE TEAM GENIUS 24
0 · Reply
TruthBroker2
TruthBroker2 Oct. 24 at 1:55 AM
$SMMT $PLSE
0 · Reply
TruthBroker2
TruthBroker2 Oct. 21 at 1:28 PM
$PLSE $SMMT
0 · Reply
TruthBroker2
TruthBroker2 Oct. 13 at 3:07 PM
$PLSE
0 · Reply
ZacksResearch
ZacksResearch Oct. 13 at 12:31 PM
$PLSE's cardiac innovation — a potential shift for AF treatment? 💥 The nPulse Cardiac Surgical System shows 94% success in pulmonary vein isolation with no severe complications in the high-dose group, positioning it as a disruptive option against traditional thermal methods. 🔍 Discover the full clinical insights here 👉 https://www.zacks.com/stock/news/2767188/pulse-biosciences-unveils-promising-first-in-human-data-for-npulse?cid=sm-stocktwits-2-2767188-body-15676&ADID=SYND_STOCKTWITS_TWEET_2_2767188_BODY_15676
0 · Reply
ZacksResearch
ZacksResearch Oct. 13 at 11:31 AM
Breakthrough alert: $PLSE just dropped first-in-human data for its nPulse system 🚀 Early results show safety, rapid procedure times, and strong potential for durable AF treatment — a major milestone for its cardiac tech platform. See the full data and what it means for PLSE’s future here 👉 https://www.zacks.com/stock/news/2767188/pulse-biosciences-unveils-promising-first-in-human-data-for-npulse?cid=sm-stocktwits-2-2767188-teaser-15675&ADID=SYND_STOCKTWITS_TWEET_2_2767188_TEASER_15675
0 · Reply
TruthBroker2
TruthBroker2 Oct. 10 at 1:16 PM
$PLSE $SMMT
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 10 at 12:50 PM
$PLSE (+3.9% pre) Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting https://ooc.bz/l/80079
0 · Reply
DARKP00L
DARKP00L Oct. 10 at 11:04 AM
$PLSE 07:02 on Oct. 10 2025 Pulse Biosciences Announces Late-Breaking Clinical Study Results From nPulse Cardiac Surgical System First-In-Human Feasibility Study At 39th European Association For Cardio-Thoracic Surgery Annual Meeting #tradeideas
1 · Reply
TruthBroker2
TruthBroker2 Oct. 9 at 1:18 PM
$SMMT $PLSE
0 · Reply
Latest News on PLSE
Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

Oct 24, 2025, 7:00 AM EDT - 4 days ago

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025

Oct 22, 2025, 4:05 PM EDT - 5 days ago

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 16, 2025, 7:00 AM EDT - 12 days ago

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Oct 10, 2025, 7:00 AM EDT - 18 days ago

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Oct 7, 2025, 7:00 AM EDT - 21 days ago

Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Pulse Biosciences' nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting

Sep 10, 2025, 7:00 AM EDT - 6 weeks ago

Pulse Biosciences' nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting

Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation

Sep 8, 2025, 7:00 AM EDT - 7 weeks ago

Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation

Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study

Sep 2, 2025, 7:00 AM EDT - 2 months ago

Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study

Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid

Aug 26, 2025, 7:00 AM EDT - 2 months ago

Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid

Pulse Biosciences, Inc. (PLSE) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 9:06 PM EDT - 2 months ago

Pulse Biosciences, Inc. (PLSE) Q2 2025 Earnings Call Transcript

Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results

Aug 12, 2025, 4:05 PM EDT - 2 months ago

Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results

Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference

Aug 1, 2025, 7:00 AM EDT - 3 months ago

Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference

Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025

Jul 29, 2025, 4:05 PM EDT - 3 months ago

Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025

Pulse Biosciences, Inc. (PLSE) Q1 2025 Earnings Call Transcript

May 10, 2025, 11:02 PM EDT - 6 months ago

Pulse Biosciences, Inc. (PLSE) Q1 2025 Earnings Call Transcript

Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 6 months ago

Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference

May 6, 2025, 4:05 PM EDT - 6 months ago

Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting

May 1, 2025, 7:00 AM EDT - 6 months ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting

Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025

Apr 24, 2025, 4:05 PM EDT - 6 months ago

Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting

Apr 23, 2025, 7:00 AM EDT - 6 months ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting

Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 7:46 PM EDT - 7 months ago

Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

Mar 27, 2025, 4:05 PM EDT - 7 months ago

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference

Mar 26, 2025, 4:05 PM EDT - 7 months ago

Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference

Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025

Mar 7, 2025, 8:00 AM EST - 8 months ago

Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025

Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 4:05 PM EST - 8 months ago

Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference

Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

Feb 4, 2025, 8:00 AM EST - 9 months ago

Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

Pulse Biosciences' Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting

Jan 30, 2025, 8:00 AM EST - 9 months ago

Pulse Biosciences' Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium

Jan 21, 2025, 7:00 AM EST - 10 months ago

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium

Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

Jan 13, 2025, 7:00 AM EST - 10 months ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer

Jan 10, 2025, 8:00 AM EST - 10 months ago

Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer

Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 9:00 AM EST - 10 months ago

Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Dec 23, 2024, 4:30 PM EST - 11 months ago

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants

Dec 19, 2024, 8:00 AM EST - 11 months ago

Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants

Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery

Dec 17, 2024, 8:00 AM EST - 11 months ago

Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

Oct 31, 2024, 2:25 PM EDT - 1 year ago

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 9:42 PM EDT - 1 year ago

Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript

Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

Oct 30, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

Oct 30, 2024, 4:02 PM EDT - 1 year ago

Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024

Oct 21, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024

Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 6:50 PM EDT - 1 year ago

Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript

Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024

Jul 29, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Jul 8, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc. Announces the Closing of its Rights Offering

Jul 3, 2024, 2:44 PM EDT - 1 year ago

Pulse Biosciences, Inc. Announces the Closing of its Rights Offering

Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering

Pulse Biosciences, Inc. Announces Commencement of Rights Offering

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences, Inc. Announces Commencement of Rights Offering

Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000

May 20, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000

TruthBroker2
TruthBroker2 Oct. 27 at 12:18 PM
$SMMT $PLSE TEAM GENIUS 24
0 · Reply
TruthBroker2
TruthBroker2 Oct. 24 at 1:55 AM
$SMMT $PLSE
0 · Reply
TruthBroker2
TruthBroker2 Oct. 21 at 1:28 PM
$PLSE $SMMT
0 · Reply
TruthBroker2
TruthBroker2 Oct. 13 at 3:07 PM
$PLSE
0 · Reply
ZacksResearch
ZacksResearch Oct. 13 at 12:31 PM
$PLSE's cardiac innovation — a potential shift for AF treatment? 💥 The nPulse Cardiac Surgical System shows 94% success in pulmonary vein isolation with no severe complications in the high-dose group, positioning it as a disruptive option against traditional thermal methods. 🔍 Discover the full clinical insights here 👉 https://www.zacks.com/stock/news/2767188/pulse-biosciences-unveils-promising-first-in-human-data-for-npulse?cid=sm-stocktwits-2-2767188-body-15676&ADID=SYND_STOCKTWITS_TWEET_2_2767188_BODY_15676
0 · Reply
ZacksResearch
ZacksResearch Oct. 13 at 11:31 AM
Breakthrough alert: $PLSE just dropped first-in-human data for its nPulse system 🚀 Early results show safety, rapid procedure times, and strong potential for durable AF treatment — a major milestone for its cardiac tech platform. See the full data and what it means for PLSE’s future here 👉 https://www.zacks.com/stock/news/2767188/pulse-biosciences-unveils-promising-first-in-human-data-for-npulse?cid=sm-stocktwits-2-2767188-teaser-15675&ADID=SYND_STOCKTWITS_TWEET_2_2767188_TEASER_15675
0 · Reply
TruthBroker2
TruthBroker2 Oct. 10 at 1:16 PM
$PLSE $SMMT
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 10 at 12:50 PM
$PLSE (+3.9% pre) Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting https://ooc.bz/l/80079
0 · Reply
DARKP00L
DARKP00L Oct. 10 at 11:04 AM
$PLSE 07:02 on Oct. 10 2025 Pulse Biosciences Announces Late-Breaking Clinical Study Results From nPulse Cardiac Surgical System First-In-Human Feasibility Study At 39th European Association For Cardio-Thoracic Surgery Annual Meeting #tradeideas
1 · Reply
TruthBroker2
TruthBroker2 Oct. 9 at 1:18 PM
$SMMT $PLSE
0 · Reply
TruthBroker2
TruthBroker2 Oct. 8 at 12:31 PM
$PLSE
0 · Reply
liloleme4
liloleme4 Oct. 3 at 3:29 PM
$PLSE Up nicely today and can't find a word about it, even on ST... Perhaps I've blocked too many bots?
0 · Reply
TruthBroker2
TruthBroker2 Oct. 3 at 12:59 PM
$PLSE Be lookin Good
0 · Reply
Doozio
Doozio Oct. 3 at 11:04 AM
It was always 🐒🍌🧠⏰♾️ wen da 🐑 wud get a $PLSE as the GRRR’s turned to MLYS then became BILI’s as its $LIVE in this $GME
0 · Reply
TruthBroker2
TruthBroker2 Oct. 2 at 1:30 PM
$SMMT $PLSE
0 · Reply
TruthBroker2
TruthBroker2 Oct. 1 at 3:19 PM
$PLSE $SMMT
0 · Reply
TruthBroker2
TruthBroker2 Sep. 29 at 11:18 AM
$SMMT $PLSE
0 · Reply
TruthBroker2
TruthBroker2 Sep. 26 at 1:36 PM
$PLSE
0 · Reply
Elean001
Elean001 Sep. 25 at 11:18 PM
$PLSE $SMMT
0 · Reply
TruthBroker2
TruthBroker2 Sep. 25 at 11:25 AM
$PLSE $SMMT
0 · Reply
TruthBroker2
TruthBroker2 Sep. 24 at 2:05 PM
$SMMT $PLSE
0 · Reply
LeisureSuitLarry
LeisureSuitLarry Sep. 22 at 10:27 PM
$PLSE
0 · Reply